Qubiotech is a company active in the identification, preparation and management of R + D + i projects. Our interests in this activity lie in neurodegeneration and ICT solutions with artificial intelligence to support diagnosis.
If you have a project idea and are looking for a partner, do not hesitate to contact us!
 |
 |
 |
 |
The aim of the project is to develop a new technology that allows early diagnosis and non-invasive monitoring of the most aggressive brain tumours with the lowest life expectancy for patients, such as glioblastomas. Currently, diagnosis requires biopsies of tumour tissue by neurosurgery, an operation that requires a great deal of planning and is traumatic for patients. In other types of tumours, however, it has been possible to apply immuno-PET techniques for tumour characterisation using antibodies linked to Positron Emission Tomography (PET) radiotracers, which allow the tumour to be diagnosed without the need to remove the tissue. However, in brain tumours, the blood-brain barrier, a film that protects the brain from the entry of foreign substances into the body, has prevented the application of these non-invasive techniques. The DIAGBI project aims to overcome this barrier by using nanoparticles, capable of penetrating it, to carry PET tracers along with the antibodies needed for genetic characterisation of the tumour. In this way, it would be possible to speed up diagnosis and follow-up times and avoid difficult and costly neurosurgical interventions. The ultimate goal is to improve and extend the quality of life of patients and to make more efficient use of health care resources.
Qubiotech Health Intelligence participates in the project “MOBILE HEALTH SOLUTION BASED ON GENETIC PROFILE, IMAGE ANALYSIS AND CONTINUOUS MONITORING OF SYMPTOMS FOR THE PERSONALIZED MANAGEMENT OF PATIENTS WITH PARKINSON’S DISEASE (GiMO-PD) funded by the Ministry RTC2019-7150-1” of Science and Innovation.
The project, which will take place between 2020 and 2023, will be developed by a consortium of 3 companies and two public research organizations and aims to develop a solution that can be integrated into the healthcare circuit that facilitates the diagnosis and monitoring of patients with Parkinson. In this project, Qubiotech is responsible for the development of a SPECT image analysis software that identifies biomarkers of image characteristic of the disease for its later integration with other clinical data and to develop evaluation models and disease progression.
Qubiotech has been one of the 15 European start-ups participating in the accelerator of the European Institute of Technology – Health Product / Market Fit. This project will allow us to access the British market more quickly.
Qubiotech has been one of the three Galician companies benefiting from the NEOTEC Grants (CDTI) in the 2016 call. This aid of € 200,000 will allow the development of new products and their commercialization in Spain and Europe.
Qubiotech has been selected for the granting of the IGAPE Re-Acciona aid to improve competitiveness.
